Metacrine, Inc. (MTCR)
Market Cap | 24.81M |
Revenue (ttm) | n/a |
Net Income (ttm) | -38.19M |
Shares Out | 43.83M |
EPS (ttm) | -1.03 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 78,494 |
Open | 0.575 |
Previous Close | 0.567 |
Day's Range | 0.566 - 0.575 |
52-Week Range | 0.303 - 0.676 |
Beta | -0.77 |
Analysts | Sell |
Price Target | 0.51 (-9.89%) |
Earnings Date | May 10, 2023 |
About MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MTCR stock is "Sell." The 12-month stock price forecast is $0.51, which is a decrease of -9.89% from the latest price.
News

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. ...

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.
NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Co...

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.
NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Co...

Metacrine Reports Third-Quarter 2022 Results
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL
NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR
NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Metacrine, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - September 8, 2022) - Rigrodsky Law, P.A. is investigating Metacrine, Inc. ("Metacrine") (NASDAQ: MTCR) regarding possible breaches of fiduciary duties and other...

MTCR Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Metacrine Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Metacrine Inc. (NASDAQ: MTCR) and Equillium, Inc. is fair to Metacrine shareholders. Ha...

Equillium to Acquire Metacrine in All-Stock Transaction
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement ...

Metacrine Reports Second-Quarter 2022 Results
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, ...

Metacrine Reports First-Quarter 2022 Results
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, t...

Metacrine Reports Fourth-Quarter 2021 Results
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases,...

Metacrine Announces Executive Leadership Changes
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, ...

Metacrine To Slash Its Workforce By 50%
Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in...

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

Metacrine Announces Resignation of Chief Medical Officer
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.

Metacrine Reports Third-Quarter 2021 Results
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...

Metacrine to Present at 2021 Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...